Oncor sells business division to Ventana
This article was originally published in Clinica
Oncor has sold assets relating to its in situ hybridisation business, including the Inform Her-2/Neu test for the detection of breast cancer, to Ventana Medical Systems for a total of up to $5.5 million. The company voluntarily surrendered assets relating to the business to secured creditors, who sold it to Ventana with Oncor's permission.
You may also be interested in...
Nina Daily, chief marketing officer at the Professional Beauty Association since July 2018, will succeed Steve Sleeper as executive director at the end of June when Sleeper retires. More cosmetics industry appointments.
Third round of orders would give the US all the vaccine it needs from the existing mRNA products, taking pressure off AstraZeneca as it experiences manufacturing challenges and the EU considers export restrictions to ensure it gets enough vaccine.
Listerine mouthwash drove J&J’s oral care sales up 11.4% in the fourth quarter. Tylenol for adults was the star of its OTC drug business but weakness of children’s Tylenol products and other OTCs led to flat sales.